Your shopping cart is currently empty

NBQX disodium is a highly selective, competitive AMPA receptor antagonist with neuroprotective and anticonvulsant activity. NBQX disodium is a salt of NBQX. NBQX disodium is a potent and selective AMPA/rhodosinate receptor antagonist that can be used to antagonize the excitatory toxicity of glutamate. It has anticonvulsant effects in rodent models.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $35 | In Stock | In Stock | |
| 5 mg | $80 | In Stock | In Stock | |
| 10 mg | $123 | In Stock | In Stock | |
| 25 mg | $247 | In Stock | In Stock | |
| 50 mg | $372 | In Stock | In Stock | |
| 100 mg | $558 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $88 | In Stock | In Stock |
| Description | NBQX disodium is a highly selective, competitive AMPA receptor antagonist with neuroprotective and anticonvulsant activity. NBQX disodium is a salt of NBQX. NBQX disodium is a potent and selective AMPA/rhodosinate receptor antagonist that can be used to antagonize the excitatory toxicity of glutamate. It has anticonvulsant effects in rodent models. |
| Targets&IC50 | AMPA:0.7 ± 0.1 μM, Kainic acid:0.7 ± 0.03 μM |
| In vitro | In HIP-009 cells, NBQX disodium salt inhibited both AMPA or kainic acid (KA) induced signals in a concentration-dependent manner, with IC50 values being 0.7 ± 0.1 and 0.7 ± 0.03 μM, respectively. The AMPA-evoked calcium rise was completely inhibited by NBQX disodium salt, whereas 68.6% ± 1.3% inhibition of the KA-induced signal was observed with 30 μM of NBQX disodium salt treatment.[1] |
| In vivo | Administration of NBQX disodium (FG9202; 20 mg/kg, i.p.; for 3 days) exhibits a reduction in PTZ-induced seizures. [2] In a rat model of focal ischemia, NBQX disodium demonstrates neuroprotective effects when administered intravenously as a bolus dose of 30 mg/kg at the time of MCA occlusion, followed by an additional dose at 1 hour post-occlusion. [3] |
| Synonyms | NBQX 2Na, FG9202 disodium |
| Molecular Weight | 380.2415 |
| Formula | C12H6N4Na2O6S |
| Cas No. | 479347-86-9 |
| Smiles | O=C1[N-]C2=C([N-]C1=O)C3=CC=CC(S(=O)(N)=O)=C3C([N+]([O-])=O)=C2.[Na+].[Na+] |
| Storage | store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | H2O: 30 mg/mL (78.9 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.26 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
H2O
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.